SAN DIEGO, Sept. 6, 2018 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that two poster presentations featuring clinical
data sets using its Target Selector™ liquid biopsy platform will be
presented at the International Association for the Study of Lung
Cancer (IASLC) 19th World Conference on Lung
Cancer. The conference is being held September 23-26, 2018 in Toronto at the Metro Toronto Convention
Centre.
Details for the poster presentations are as follows:
Title: Analysis and Monitoring CTCs and ctDNA in CSF
Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC
Patients with LM
Session Category/Title: P1.01-Advanced NSCLC
Session Date and Time: Monday,
September 24, 2018 at 9:45 a.m.-12:00
p.m. EDT
Location: Metro Toronto
Convention Centre North Building, Exhibit Hall
Link to Abstract
Title: Clinical Utility of Circulating Tumor Cell (CTC)
Analysis Using Target Selector™ in Metastatic NSCLC Chemotherapy
Patients
Session Category/Title: P2.01-Advanced NSCLC
Session Date and Time: Tuesday,
September 25, 2018 at 9:45 a.m.-12:00
p.m. EDT
Location: Metro Toronto
Convention Centre North Building, Exhibit Hall
Link to Abstract
"The interim results of our analysis of circulating tumor cells
(CTC) in patients with advanced stage lung cancer receiving
chemotherapy suggest that CTC enumeration may have prognostic and
predictive potential for assessing therapeutic benefit," said
Janakiraman Subramanian, MD, MPH,
Director of Thoracic Oncology at the Saint Luke's Cancer Institute
and Assistant Professor of Medicine at University of Missouri, Kansas City. "Our
preliminary analysis shows that CTC count declines within a week
after starting chemotherapy in the majority of patients with
detectable CTCs, therefore, we will continue to study this
methodology and its potential utility in clinical practice."
"The ability to evaluate tumor markers in the cerebrospinal
fluid (CSF) of lung cancer patients is potentially an important use
of liquid biopsy when metastases to the central nervous system is
suspected or diagnosed," said Santosh
Kesari, MD, PhD, Chair and Professor, Department of
Translational Neurosciences and Neurotherapeutics, Director of
Neuro-oncology at the Pacific Neuroscience Institute and John Wayne
Cancer Institute. "Our poster shows that assays from Biocept
detected alterations in the CSF of patients that were concordant
with original tissue biopsies and blood samples, and serial
monitoring of tumor markers in the blood and CSF were consistent
with the overall clinical course of disease. Serial monitoring of
the CSF with CTCs and circulating tumor DNA (ctDNA) holds promise
for evaluating drug response and disease progression, and may
provide critical information for the management of cancer patients
with leptomeningeal disease."
"We believe that presenting data highlighting the performance of
our Target Selector™ assays at major medical conferences such as
this year's World Conference on Lung Cancer is critical to driving
physician adoption," said Biocept's President and CEO Michael Nall. "In a clinical trial for the drug
candidate tesevatinib, our technology demonstrated the ability to
detect and monitor actionable biomarkers in the cerebrospinal fluid
of patients whose lung cancer had metastasized to the central
nervous system, while the other poster presentation shows how our
CTC platform can be prognostic and predictive for disease
progression and treatment. We believe that these clinical results
support the versatility and clinical utility of our proprietary
liquid biopsy platform, which can help physicians select better
treatment pathways to improve patient outcomes."
About the IASLC 19th World Conference on Lung
Cancer (WCLC)
The WCLC is the world's largest meeting
dedicated solely to lung cancer and other thoracic malignancies,
and is expected to convene over 7,000 researchers, physicians,
specialists, patients, advocates and industry members from around
the world. The WCLC's scientific program features a line-up of
global leaders in the field. Presentations focus on cutting-edge
science, including the latest breakthroughs in targeted therapies
and immunotherapies; advances in screening, early detection and
staging; prevention and smoking cessation efforts; patient advocacy
initiatives; and much more. Collaboration across disciplines and
borders is a meeting highlight. The WCLC's scientific program is
available to review online.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the
platform has demonstrated the ability to identify cancer mutations
and alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
outcomes of patients diagnosed with cancer, the versatility and
clinical utility of our proprietary liquid biopsy platform, and our
ability to increase physician adoption of our liquid biopsy
platform , such statements are forward-looking, and are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The reader is cautioned not to put
undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
Securities and Exchange Commission (SEC) filings. The effects of
such risks and uncertainties could cause actual results to differ
materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law. Readers are advised to review our filings with the SEC, which
can be accessed over the Internet at the SEC's website located at
www.sec.gov.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biocepts-target-selector-platform-featured-in-two-poster-presentations-at-the-iaslc-19th-world-conference-on-lung-cancer-300707838.html
SOURCE Biocept, Inc.